Inflammatory bowel disease (IBD) is frequently diagnosed among reproductive-aged women, with 25% of women conceiving after diagnosis [1]. Associations of IBD with pregnancy outcomes have been extensively reported [2–6]. It has been well established, that achieving disease remission prior to conception is important to improve maternal and perinatal outcomes [4–6]. In addition, disease flares throughout gestation are not uncommon, occurring in approximately a third of women [4–6], and have been shown to increase the rate of adverse outcomes including fetal loss, preterm birth and the delivery of a small-for-gestational-age infant [1,7,8].
